Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bornem – page 120

2 138 clinical trials in Bornem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bornem at a glance
2 138
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 138 trials in Bornem

Open in trial search

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Radboud universitair medisch centrum Stichting

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:QEL-001
  • Sponsor:Quell Therapeutics Limited

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety of Glepaglutide for Adults with Short Bowel Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Elafibranor for Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Pharma

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bornem

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colon cancer treatment and survival outcomes. Research explores the potential benefits of common medications in cancer recurrence prevention.

  • Cancer Survival Studies
  • Preventive Medicine
  • Post-Surgery Care

The study examines how acetylsalicylic acid therapy might improve long-term survival rates for patients who have undergone colon cancer surgery, specifically targeting stage II and III cases.

02 Preventive Medicine

Investigation into the role of daily aspirin therapy in preventing cancer recurrence, representing an innovative approach to post-operative care in oncology.

  • Long-term Patient Care
  • Drug Repurposing
  • Cancer Prevention

This research explores how commonly available medications might be repurposed to enhance cancer treatment outcomes and improve patient survival rates.

03 Surgical Oncology

Studies focusing on patients with resected colon carcinoma, examining post-surgical interventions that may enhance treatment success.

  • Post-Operative Care
  • Cancer Recovery
  • Treatment Optimization

Research aimed at developing comprehensive treatment strategies that combine surgical intervention with long-term preventive measures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.